新型口服抗凝剂在肿瘤相关静脉血栓栓塞症治疗中的应用

唐亮; 胡豫

doi:10.13201/j.issn.1004-2806.2019.01.001

新型口服抗凝剂在肿瘤相关静脉血栓栓塞症治疗中的应用

唐亮,
胡豫^,

- 华中科技大学同济医学院附属协和医院血液病研究所(武汉, 430022)

详细信息

通讯作者: 胡豫,E-mail:dr_huyu@126.com

中图分类号: R554.1

收稿日期: 2018-12-10

Application of novel oral anticoagulants for venous thromboembolism in patients with cancer

TANG Liang,
HU Yu^,

More Information

Corresponding author: HU Yu, E-mail: dr_huyu@126.com

Received Date: 10 December 2018

摘要

- 静脉血栓栓塞症 /
- 恶性肿瘤相关血栓形成 /
- 抗凝治疗 /
- 新型口服抗凝剂 /
- 低分子量肝素
- venous thromboembolism /
- cancer-associated thrombosis /
- anticoagulant therapy /
- novel oral antico agulant /
- low molecular weight heparin

HTML全文

参考文献(18)

[1]	Timp JF, Braekkan SK, Versteeg HH, et al.Epidemiology of cancer-associated venous thrombosis[J].Blood, 2013, 122:1712-1723.
[2]	Chew HK, Wun T, Harvey D, et al.Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J].Arch Intern Med, 2006, 166:458-464.
[3]	Prandoni P, Lensing AW, Piccioli A, et al.Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis[J].Blood, 2002, 100:3484-3488.
[4]	Lyman GH, Khorana AA, Kuderer NM, et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update[J].J Clin Oncol, 2013, 31:2189-2204.
[5]	Lee AY, Levine MN, Baker RI, et al.Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J].N Engl J Med, 2003, 349:146-153.
[6]	Lyman GH, Bohlke K, Khorana AA, et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update 2014[J].J Clin Oncol, 2015, 33:654-656.
[7]	Munoz Martin AJ, Font Puig C, Navarro Martin LM, et al.Clinical guide SEOM on venous thromboembolism in cancer patients[J].Clin Transl Oncol, 2014, 16:1079-1090.
[8]	Farge D, Bounameaux H, Brenner B, et al.International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer[J].Lancet Oncol, 2016, 17:e452-e466.
[9]	NCCN Clinical Practice Guidelines in Oncology.Venous thromboembolic disease.V2.2018.http://www.nccn.org.Accessed 24 Oct 2018.
[10]	Guyatt GH, Akl EA, Crowther M, et al.Introduction to the ninth edition:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest, 2012, 141:48S-52S.
[11]	Mandala M, Falanga A, Roila F, et al.Management of venous thromboembolism (VTE) in cancer patients:ESMO Clinical Practice Guidelines[J].Ann Oncol, 2011, 22:vi85-vi92.
[12]	Schulman S, Goldhaber SZ, Kearon C, et al.Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer[J].Thromb Haemost, 2015, 114:150-157.
[13]	Prins MH, Lensing AW, Brighton TA, et al.Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE):apooled subgroup analysis of two randomised controlled trials[J].Lancet Haematol, 2014, 1:e37-e46.
[14]	Agnelli G, Buller HR, Cohen A, et al.Oral apixaban for the treatment of venous thromboembolism in cancer patients:results from the AMPLIFY trial[J].J Thromb Haemost, 2015, 13:2187-2191.
[15]	Raskob G, Buller H, Prins M, et al.Edoxaban for the long-term treatment of venous thromboembolism:rationale and design of the Hokusai-venous thromboembolism study——methodological implications for clinical trials[J].J Thromb Haemost, 2013, 11:1287-1294.
[16]	Posch F, Konigsbrugge O, Zielinski C, et al.Treatment of venous thromboembolism in patients with cancer:A network meta-analysis comparing efficacy and safety of anticoagulants[J].Thromb Res, 2015, 136:582-589.
[17]	Young AM, Marshall A, Thirlwall J, et al.Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:results of a randomized trial (SELECT-D)[J].J Clin Oncol, 2018, 36:2017-2023.
[18]	Raskob GE, van Es N, Verhamme P, et al.Edoxaban for the treatment of cancer-associated venous thromboembolism[J].N Engl J Med, 2018, 378:615-624.